-
Posted by
Two Blokes May 4 -
Filed in
Stock
-
1 view
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) outlined recent developments across its pipeline following the release of its 2024 results. The company said it had made progress on multiple fronts, including its core MASH program, additional indications such as Werner syndrome and sarcopenia, and a newly initiated proof-of-concept study in dogs.
